Introduction
============

Colon cancer is one of the most common types of tumors in humans.[@b1-cmar-10-5479] Many researchers have shown that SMAD4 is frequently lost in colon cancers, which is associated with the development of metastases and a poor prognosis.[@b1-cmar-10-5479],[@b2-cmar-10-5479] Smad4 mutations were observed in 95% invasive and metastatic colon cancers.[@b2-cmar-10-5479] Many studies have demonstrated the Smad4 pathway has been shown to mediate the antimetastatic role in colon cancer metastasis.[@b1-cmar-10-5479]--[@b3-cmar-10-5479],[@b9-cmar-10-5479]--[@b15-cmar-10-5479] This study and other researcher's previous studies found that Smad4 was associated with poor prognosis in patients with colon cancer and inhibited tumor metastasis through multiple processes, including the inhibition of apoptosis and inhibition of the epithelial--mesenchymal transition (EMT) process, and phosphatidylinositol 3-kinase--Akt (PI3K--Akt) signaling pathway.[@b1-cmar-10-5479]--[@b3-cmar-10-5479],[@b9-cmar-10-5479],[@b15-cmar-10-5479],[@b25-cmar-10-5479] However, the exact mechanism remains unclear. Therefore, studying the role of Smad4 in tumor metastasis is essential for developing more effective treatments and improving colon cancer patients' prognosis.

Recently, many miRNAs-related metastasis gene have been identified.[@b4-cmar-10-5479],[@b5-cmar-10-5479] miRNAs are 20--22 nucleotide endogenous noncoding RNAs, which repress target gene expression at the post-transcriptional level and are now considered to be major regulators of gene expression for at least 30% of human genes.[@b5-cmar-10-5479]--[@b7-cmar-10-5479] Functional studies indicate that miRNAs have important functions in tumor progression, especially recurrence, drug resistance, and metastasis.[@b4-cmar-10-5479]--[@b8-cmar-10-5479] A lot of researchers have provided strong evidence that miRNAs play an important role during tumorigenesis and tumor progression.[@b4-cmar-10-5479]--[@b8-cmar-10-5479]

Given that miRNAs play a significant role in gene regulation and tumorigenesis, and Smad4 is the central component of the TGF-β and bone morphogenetic protein signaling pathway which plays an important role in cancer progression, miRNAs might interact with the Smad superfamily in tumors.[@b6-cmar-10-5479],[@b7-cmar-10-5479] Thus, we hypothesized that Smad4 may mediate the activation or inhibition of miRNAs, which could influence colon cancer metastasis. Until now, there are no reports about the miRNA expression profile following smad4 reexpression in a colon cancer cell model. In this study, we profiled the miRNAs of the SW620 colon cancer cell line transfected with smad4 lentiviral vector, which can get stable reexpression of Smad4. Fifty-three known miRNAs were found to be differentially expressed. Some of the differentially expressed miRNAs might be potential biomarkers for colon cancer. Thus, we provide a new context to study the mechanism by which Smad4 inhibited tumor metastasis.

Materials and methods
=====================

Establishment of colon cancer cell lines with stable overexpression of Smad4
----------------------------------------------------------------------------

Human colon adenocarcinoma cell line SW620, which was derived from lymph node metastasis and does not express Smad4, was obtained from American Type Culture Collection (Manassas, VA) and was cultured in RPMI 1640 media supplemented with 10% FBS. The full-length coding region of Smad4 gene was amplified with PCR, and the amplified fragment was cloned into the lentiviral vector GV248. The recombinant lentiviral vector was transfected into 293 T cells for packaging the virus, which was then transfected into colon cancer SW620 cells. The stably transfected cells were selected with G418, and the cellular expressions of Smad4 mRNA and protein were detected using quantitative PCR and Western blotting (WB).

smRNA library construction and next-generation sequencing
---------------------------------------------------------

Six samples were selected randomly each from control group (smad4-negative cells) and Smad4 group (Smad4-positive cells), and sequenced by second-generation illumina high-throughput sequencing, screened for differentially expressed miRNA. Briefly, total RNA was collected from three pairs of Smad4-positive cells and matched smad4-negative cells by using TRIzol reagent (Life Technologies, Carlsbad, CA, USA). Qualified RNA with A260/A280 ratio more than 1.8 was subsequently assessed for RNA integrity by conducting the DNA chip assay. smRNA libraries were constructed by using a smRNA sample prep kit (Illumina, San Diego, CA, USA) following the standard protocols. Eventually, the libraries which were constructed from three independent Smad4-positive cells and three matched independent smad4-negative cells were sequenced by applying Illumina HiSeq 2500 (Illumina, USA) at GENE DENOVO (Guangzhou, People's Republic of China) strictly following the standard protocols.

Data analysis
-------------

Consensus Assessment of Sequence and Variation (version 1.8.2; all Illumina, Inc.), Illumina HiSeq Control software (version 2.0.12), and Real-Time Analysis software (version 1.12.4.2) were applied to analyze the raw data. Differential expression levels of miRNA were calculated and standardized to reads per million, as follows: Counts/total count of each sample ×1 million. Target genes of differentially expressed miRNAs were predicted using the TargetScan database, miRDB database, and miRanda database, which were downloaded from <http://www.targetscan.org/>, <http://www.mirdb.org/>, and <http://www.microrna.org/>, respectively. The predicted genes underwent Gene Ontology (GO; <http://www.geneontology.org/>) and Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg/>) pathway analyses using the functional annotation tools of the Database from Annotation, Visualization, and Integrated Discovery (DAVID; <http://david.abcc.Ncifcrf.gov/>). The enrichment of GO terms and KEGG pathways were selected using a cutoff standard of *P*\<0.01 and false discovery rate\<1.

Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
----------------------------------------------------------------------

Smad4-negative cells and Smad4-positive cells were collected. Following total RNA isolation, cDNA were synthesized using a miDETECT A Track™ miRNA qRT-PCR Starter kit (RIOB IO Biotechnology Co., Ltd., Guangzhou, People's Republic of China). All the miRNA primers (miDETECT A TrackTM miRNA qPCR Primer Set, including hsa-miR-323b-3p, hsa-miR-323b-3p, hsa-miR-371a-5p, hsa-miR-708-3p, hsa-miR-6852-5p, hsa-miR-767-5p, hsa-miR-382-5p, hsa-miR-514a-3p, hsa-miR-1289, hsa-miR-1537-5p, hsa-miR-23c, hsa-miR-3199, hsa-miR-3619-5p, hsa-miR-3657, hsa-miR-548u, hsa-miR-5699-5p, hsa-miR-874-5p) and control primer (miDETECT A TrackTM U6 qPCR Primer Set) were also purchased from this company. qPCR was performed on an ABI 7500 real-time PCR system (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer's protocol by miDETECT A TrackTM miRNA qPCR kit (RIOB IO Biotechnology Co., Ltd.). Dissociation curve analysis was used to verify the generation of single products. U6 was used as a reference gene, and all reactions were repeated three times. Data were analyzed using the ABI 7500 Prism sequence detection software (Applied Biosystems) and the relative expression was calculated using the 2−^ΔΔCq^ method.

WB
--

Total cell extracts were prepared in a lysis buffer (Solarbio, Peking, People's Republic of China). After 10 minutes on ice, cell debris was removed by centrifugation at 10,000 g for 10 minutes. Protein concentrations were determined by the BCA method (Sigma, Santa Clara, CA, USA) using BSA as a control. Proteins were separated by SDS-PAGE and then transferred onto polyvinylidene difluoride membranes (Minipore, Billerica, MA, USA), which were treated with the appropriate primary antibodies (Abcam, UK). Antibody-bound proteins were detected by a chemiluminescence method according to the manufacturer's protocol (CB Company, Murray, UT, USA).

Migration and invasion assays
-----------------------------

Human colon cancer cell line SW480, which does not express Smad4, and RKO, HCT116, LOVO, and HCT8 cell lines were obtained from American Type Culture Collection and were cultured in RPMI 1640 media supplemented with 10% FBS. Transwell Cell Migration and Invasion Assay kit (BD Biosciences, Franklin Lakes, NJ, USA) was used to analyze cell migration and invasion ability strictly following the standard protocols. Generally, a transwell chamber was placed into a 24-well plate and was coated with 30 µL matrigel and was incubated for 40 minutes at 37°C for the invasion assay. In both transwell assay, stably transfected cells were trypsinized and seeded in chambers and cultured, while 600 µL medium was added to the lower chamber. About 24 hours later, migrated cells were fixed with 100% methanol for 30 minutes. Nonmigrated cells were removed. Then cells on bottom surface of the membrane were stained by crystal violet for 20 minutes. Cell images were obtained under a phase-contrast microscope (Olympus, Tokyo, Japan).

Statistical analysis
--------------------

Statistical analysis was performed using SPSS statistical software (version 17.0; SPSS, Inc., Chicago, IL, USA). The significant difference between the two groups was analyzed by one-way analysis of variance using paired *t*-test. Data are expressed as mean ± SD. *P*\<0.05 was considered as significant difference.

Results
=======

Stable overexpression of Smad4 in SW620 colorectal cancer cell line
-------------------------------------------------------------------

First, we chose the SW620 human colon cancer cell model, which is null in Smad4 expression. To get the stable expression of Smad4 gene, we transfected the lentiviral Smad4 vector into the cells and got the stable cell model, SW620 Smad4, which reexpressed the gene of Smad4. As shown in [Figure 1A, B](#f1-cmar-10-5479){ref-type="fig"}, we performed WB and qRT-PCR and found that transfection of Samd4 activated the reexpression of Smad4.

miRNA expression profiles following stable Smad4 re-expression
--------------------------------------------------------------

To identify the difference in miRNA expression in control group (smad4-negative cells) and Smad4 group (Smad4-positive cells), we used the second-generation illumina high-throughput sequencing technology and screened differentially expressed miRNAs. We found that 53 differentially expressed miRNAs (including 43 upregulated and 10 downregulated known miRNAs, respectively) in the SW620-Smad4 cells in contrast to the SW620-control cells. [Table 1](#t1-cmar-10-5479){ref-type="table"} summarizes the 53 miRNAs that show the significant differences. We also found the novel differentially miRNAs expression profiles of the two cell lines, which is shown in [Table 2](#t2-cmar-10-5479){ref-type="table"}, especially, novel-m0099-5p, novel-m0100-5p, novel-m0101-5p, novel-m0102-5p, and novel-m0103-5p were reduced by about 63 times and novel-m0188-5p, novel-m0030-5p, novel-m0227-3p, novel-m0228-3p, and novel-m0251-5p were increased by about 8, 16, 23, 23, 10 times, respectively.

Validation of differentially expressed miRNAs
---------------------------------------------

miRNA-specific qRT-PCR was performed to validate the differentially expressed miRNAs. As shown in [Figure 2A](#f2-cmar-10-5479){ref-type="fig"}, the expression levels of hsa-miR-323b-3p, hsa-miR-323b-3p, hsa-miR-371a-5p, hsa-miR-708-3p, hsa-miR-6852-5p, hsa-miR-767-5p, hsa-miR-382-5p, and hsa-miR-514a-3p were significantly upregulated in SW620-Smad4 cells, whereas, as shown in [Figure 2B](#f2-cmar-10-5479){ref-type="fig"}, hsa-miR-1289, hsa-miR-1537-5p, hsa-miR-23c, hsa-miR-3199, hsa-miR-3619-5p, hsa-miR-3657, hsa-miR-548u, hsa-miR-5699-5p, and hsa-miR-874-5p were downregulated. These findings are consistent with the results of the miRNAs sequencing results.

GO analysis of predicted target genes of differentially expressed miRNAs
------------------------------------------------------------------------

To investigate the potential predicted target gene enrichment in cellular component ([Table 3](#t3-cmar-10-5479){ref-type="table"}), molecular function ([Table 4](#t4-cmar-10-5479){ref-type="table"}), and biological process ([Table 5](#t5-cmar-10-5479){ref-type="table"}), GO analysis was performed with the differentially expressed miRNAs following Smad4 reexpression. The results suggested that a lot of functional signaling pathways were enriched, including those involved in the regulation of cellular metabolic process, anatomical structure development, developmental process, and regulation of molecular-binding processes. In addition, the intracellular part exhibited the most increased enrichment of GO terms in Smad4 reexpression cell ([Table 3](#t3-cmar-10-5479){ref-type="table"}).

KEGG pathway analysis of predicted target genes of differentially expressed miRNAs
----------------------------------------------------------------------------------

KEGG pathway analysis was also performed with the differentially expressed miRNAs following Smad4 reexpression, which indicated that vascular smooth muscle contraction pathways and pathways in cancer metastasis were changed and corresponded to differentially expressed transcripts ([Table 6](#t6-cmar-10-5479){ref-type="table"}).

Validation of partial sequencing data analysis results
------------------------------------------------------

To demonstrate our hypothesis, we first screened the expression of Smad4 in six kinds of colon cancer cells including SW480, SW620, RKO, HCT116, LOVO, and HCT8. As shown in [Figure 3A](#f3-cmar-10-5479){ref-type="fig"}, the expression level of Smad4 was null in SW480 and SW620 cells, whereas RKO, HCT116, LOVO, and HCT8 cells had higher expression levels of Smad4. Then, we also transfected the lentiviral Smad4 vector into the SW480 cells and got the stable cell model, SW480 Smad4 ([Figure 3B](#f3-cmar-10-5479){ref-type="fig"}). Smad4 reexpression inhibited cell migration and invasion in SW480 ([Figure 4A, B](#f4-cmar-10-5479){ref-type="fig"}) and SW620 ([Figure 5A, B](#f5-cmar-10-5479){ref-type="fig"}) cells, which is independent of TGF-β1. Smad4 reexpression increased the expression of E-cadherin (E-cad), and decreased the Vimentin (Vim) and Matrix Metalloproteinase-9 (MMP-9) expression ([Figures 4C](#f4-cmar-10-5479){ref-type="fig"} and [5C](#f5-cmar-10-5479){ref-type="fig"}). Restoration of SMAD4 results in a marked decrease of Vim by inhibiting p-AKT and p-EPHA2, but significantly increased the E-cad by AKT--EPHA2 pathways in colon cancer SW480 cells ([Figure 6A](#f6-cmar-10-5479){ref-type="fig"}). We got the same phenomenon in colon cancer SW620 cells following stable Smad4 reexpression ([Figure 6B](#f6-cmar-10-5479){ref-type="fig"}).

Discussion
==========

Colon cancer metastasis is the leading cause of death in colon cancer patients.[@b13-cmar-10-5479] However, the molecular mechanism is not clear. Previous studies have shown that SMAD4 is strongly associated with the development of colon metastases, which plays the antimetastatic role in colon cancer metastasis.[@b14-cmar-10-5479]--[@b16-cmar-10-5479] Smad4, known as deleted in pancreatic carcinoma, locus 4 (DPC4), was first identified on the basis of frequent homozygous deletions and mutations affecting 18q21.1 in the pancreatic tumor, and was found to be involved in the TGF-β1 signaling pathway.[@b17-cmar-10-5479] The Smad4 was deregulated in many cancers and was demonstrated to mediate tumor process including pancreatic cancer, hepatocellular carcinoma, and so on.[@b17-cmar-10-5479] Some researchers have shown that Smad4 could inhibit the activity of wingless/integrated (WNT)/β-catenin signaling pathway in cancer,[@b10-cmar-10-5479] inhibit the EMT process[@b9-cmar-10-5479],[@b10-cmar-10-5479] and changes the immune microenvironment,[@b1-cmar-10-5479],[@b14-cmar-10-5479],[@b16-cmar-10-5479] which are involved in the tumor development and process.

In this study, we also demonstrate that Smad4 can regulate the migration and invasion abilities of colon cancer. However, the exact mechanism of Smad4-mediated tumor metastasis remains to be further investigated. Many studies indicate that miRNAs have important functions in tumor progression, especially recurrence, drug resistance, and metastasis.[@b4-cmar-10-5479],[@b5-cmar-10-5479],[@b8-cmar-10-5479] Ahn et al reported that Smad3 regulated, at the transcriptional level, miR-200 family members, which themselves regulate ZEB1 and ZEB2, known as transcriptional repressors of E-cad, at the post-transcriptional level in a TGF-β-independent manner, which regulate EMT in gastric cancer cells.[@b18-cmar-10-5479] Davis et al think that Smad proteins bind a conserved RNA sequence to promote miRNA maturation by Drosha. They think that Smads are multifunctional proteins that modulate gene expression transcriptionally through DNA binding and post-transcriptionally through pri-miRNA binding and regulation of miRNA processing.[@b19-cmar-10-5479] Blahna and Hata reported that Smads modulated miRNA expression through both transcriptional and post-transcriptional mechanisms: 1) transcriptional regulation of miRNAs by Smads largely resembles the canonical TGF-β signaling pathway; 2) post-transcriptional regulation of miRNA biogenesis acts on pri-miRNA in the nucleus.[@b20-cmar-10-5479],[@b21-cmar-10-5479] Therefore, we hypothesize that Smad4 could regulate the expression of miRNA and Smad4-mediated activation or inhibition of miRNAs might influence colon cancer metastasis.

As far as we know, there are no reports about the miRNA expression profile following smad4 reexpression in a colon cancer cell model. In our previous study, we identify differentially expressed miRNAs in two colon carcinoma cell lines: SW480, derived from primary colon carcinoma, and SW620, derived from lymph node metastasis, which were obtained from the same patient. And it is the first systematic analysis of the differences of miRNAs between SW480 and SW620 cells, which demonstrated the potential miRNAs biomarkers for predicting colon cancer metastasis.[@b22-cmar-10-5479] In this study, we further study the role of miRNAs in colon cancer metastasis. First, we established the colon cancer cell lines with stable overexpression of Smad4. Then, we used the next-generation sequencing technology to identify the differentially expressed miR-NAs in the SW620 colon cancer cell line transfected with smad4 lentiviral vector. We found Smad4 reexpression significantly upregulated 43 known miRNAs and downregulated 10 known miRNAs expression. Furthermore, pathway analysis of predicted miRNA targets showed that these genes were mainly involved in protein-binding transcription factor activity, vascular smooth muscle contraction, pathways in cancer metastasis, and PI3K--Akt signal pathway. We also performed qRT-PCR and WB to validate the partial results of sequencing. We demonstrated that restoration of Smad4 resulted in a marked decrease of Vim by inhibiting p-AKT and p-EPHA2, but significantly increased the E-cad by AKT--EPHA2 pathways in colon cancer SW480 cells. Many studies indicate that targeting key signaling components of PI3K--AKT pathway by restoring or inhibiting miRNA function holds promise as a potential therapeutic approach to suppress EMT in cancer[@b23-cmar-10-5479] and miRNAs could promote cell migration via the AKT signaling pathway.[@b24-cmar-10-5479]

Therefore, we speculate that Smad4 could regulate the colon cancer metastasis via a new mechanism, that is, through Smad4-miRNAs-downstream genes (such as AKT, EPHA2, E-cad, and Vim) axis. However, we should do further study to demonstrate how Smad4 regulated the expression of miRNA. We guess that Smad4 could directly mediate the miRNA expression through Smad-binding element by binding to the gene promoter zone or indirectly regulate the miRNAs expression. Of course it remains a deeply further study.

Conclusion
==========

This is the first systematic report of Smad4-mediated miRNA expression profiling in Smad4-positive and Smad4-negative SW620 human colon cancer cells, which may help us better understand the role of Smad4-mediating metastasis of colon cancer.

This work was supported by National Nature Science Foundation of China (Grant No. 81172285) and Natural Science Foundation of Fujian Province, People's Republic of China (Grant No. 2018J01392 and 2018J01390).

**Disclosure**

The authors report no conflicts of interest in this work.

![Validation of Smad4 reexpression in Smad4-negative SW620 cells by WB and qRT-PCR.\
**Notes:** (**A**) Expression of Smad4 by WB. Blank: null SW620 cells. CTRL: empty vector-infected SW620 cells. SMAD4: Smad4 vector-infected SW620 cells. β-Actin was used as an internal control. (**B**) qRT-PCR detection of Smad4 mRNA expression level in SW620 cells following Smad4 reexpression. \*\*\**P*\<0.001.\
**Abbreviations:** qRT-PCR, quantitative reverse transcription-polymerase chain reaction; WB, Western blot.](cmar-10-5479Fig1){#f1-cmar-10-5479}

![Validation of some miRNA sequencing results by qRT-PCR.\
**Notes:** (**A**) Eight upregulated miRNAs in the stable Smad4 overexpression cells group; (**B**) Ten downregulated miRNAs in the stable Smad4 overexpression cells group. U6 was used as a normalization control. Data represent the mean ± SD. of three biological replicates.\**P*\<0.05.\
**Abbreviation:** qRT-PCR, quantitative reverse transcription-polymerase chain reaction.](cmar-10-5479Fig2){#f2-cmar-10-5479}

![Generated stable Smad4 reexpression in human colon cancer cells.\
**Notes:** (**A**) Expression of Smad4 in six kinds of colon cancer cells including SW480, SW620, RKO, HCT116, LOVO, and HCT8 by WB. (**B**) WB detection of Smad4 expression level in SW480 and SW620 cells following Smad4 reexpression. β-Actin was used as an internal control. Blank: null SW620 or SW480 cells. CTRL: empty vector-infected SW620 or SW480 cells. SMAD4: Smad4 vector-infected SW620 or SW480 cells.\
**Abbreviation:** WB, Western blot.](cmar-10-5479Fig3){#f3-cmar-10-5479}

![Migration and invasion assay in SW480 cells following stable Smad4 reexpression.\
**Notes:** (**A**) Transwell cell migration and (**B**) invasion assay in Smad4-negative and Smad4-positive SW480 cells in the case of adding and without adding TGF-β1. (**C**) Protein expression level of Smad4, E-cad, Vim, and MMP-9 by WB with or without TGF-β1 cytokine. GAPDH was used as an internal control. \*\**P*\<0.01.\
**Abbreviations:** E-cad, E-cadherin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MMP-9, Matrix Metalloproteinase-9; Vim, Vimentin; WB, Western blot.](cmar-10-5479Fig4){#f4-cmar-10-5479}

![Migration and invasion assay in SW620 cells following stable Smad4 reexpression.\
**Notes:** (**A**) Transwell cell migration and (**B**) invasion assay in Smad4 negative and positive SW620 cells with or without adding TGF-β1. (**C**) WB detection of protein expression level of Smad4, E-cad, Vim, MMP-9 with or without TGF-β1 cytokine. GAPDH was used as an internal control. \*\**P*\<0.01.\
**Abbreviations:** E-cad, E-cadherin; MMP-9, Matrix Metalloproteinase-9; Vim, Vimentin; WB, Western blot.](cmar-10-5479Fig5){#f5-cmar-10-5479}

![SMAD4 reexpression modulates E-cad and Vim expression by AKT--EPHA2 signal pathways.\
**Notes:** (**A**) Restoration of SMAD4 results in a marked decrease of Vim by inhibiting p-AKT and p-EPHA2, but significantly increased the E-cad by AKT--EPHA2 pathways in colon cancer SW480 cells. (**B**) Restoration of SMAD4 results in the same phenomenon in colon cancer SW620 cells. Total protein extracted from indicated cells were lysed for WB analysis. WBs were then performed with the indicated antibodies. β-Actin served as an internal control.\
**Abbreviations:** E-cad, E-cadherin; Vim, Vimentin; WB, Western blot.](cmar-10-5479Fig6){#f6-cmar-10-5479}

###### 

Differentially expressed miRNAs between stable Smad4 overexpression cells and controls (*P*\<0.05, fold change \>2)

  miRNA              Fold change   Type of regulation   *P*-value
  ------------------ ------------- -------------------- -------------
                                                        
  hsa-miR-1-3p       3.0300481     Up                   1.68E−05
  hsa-miR-105-5p     9.63203851    Up                   0.004776827
  hsa-miR-1250-5p    2.76590929    Up                   0.016764887
  hsa-miR-127-3p     3.51000858    Up                   0.017063522
  hsa-miR-129-1-3p   20.2566667    Up                   6.26E−07
  hsa-miR-133a-3p    2.82510445    Up                   0.000749984
  hsa-miR-133a-5p    2.39407718    Up                   0.0413216
  hsa-miR-136-3p     2.87518716    Up                   0.04961782
  hsa-miR-139-5p     2.75808538    Up                   0.039079472
  hsa-miR-203a-3p    2.62724607    Up                   8.05E−05
  hsa-miR-203b-3p    2.68843604    Up                   0.000114467
  hsa-miR-3149       2.2304999     Up                   0.02335124
  hsa-miR-323b-3p    58.3133333    Up                   8.64E−05
  hsa-miR-338-5p     2.78646827    Up                   0.01011844
  hsa-miR-3656       3.98101266    Up                   0.013411597
  hsa-miR-365b-5p    23.7966667    Up                   4.75E−05
  hsa-miR-369-3p     4.58094845    Up                   0.015997829
  hsa-miR-371a-5p    41.9733333    Up                   0.003763824
  hsa-miR-376c-3p    2.58784235    Up                   0.047594468
  hsa-miR-379-5p     3.24035036    Up                   0.014697283
  hsa-miR-381-3p     2.17839525    Up                   0.040985364
  hsa-miR-382-5p     17.7724868    Up                   0.013815686
  hsa-miR-3909       2.02610176    Up                   0.003951009
  hsa-miR-409-3p     4.93321119    Up                   0.009351995
  hsa-miR-431-5p     3.59492282    Up                   0.021180118
  hsa-miR-449a       2.88279908    Up                   0.01816137
  hsa-miR-455-3p     2.13778874    Up                   0.043774928
  hsa-miR-4799-5p    20.2566667    Up                   6.26E−07
  hsa-miR-483-3p     4.37163969    Up                   0.026865568
  hsa-miR-483-5p     4.70802709    Up                   0.010097822
  hsa-miR-487b-3p    10.1258278    Up                   0.035457763
  hsa-miR-509-3p     9.46230159    Up                   0.040214237
  hsa-miR-514a-3p    15.8852097    Up                   0.02453244
  hsa-miR-548am-3p   2.49361435    Up                   0.043489873
  hsa-miR-550a-5p    2.05070751    Up                   0.021124708
  hsa-miR-656-3p     46.5566667    Up                   1.21E−06
  hsa-miR-6852-5p    20.2566667    Up                   6.26E−07
  hsa-miR-708-3p     38.0533333    Up                   0.000659703
  hsa-miR-744-5p     29.8433333    Up                   2.92E−05
  hsa-miR-758-5p     20.2566667    Up                   6.26E−07
  hsa-miR-875-5p     46.6033333    Up                   0.000407778
  hsa-miR-889-3p     2.97430749    Up                   0.012912535
  hsa-miR-767-5p     22.6434519    Up                   0.021766387
  hsa-miR-1289       2.10708403    Down                 0.048014258
  hsa-miR-1537-5p    12.0816166    Down                 0.032522333
  hsa-miR-23c        17.019999     Down                 0.000233603
  hsa-miR-3199       17.019999     Down                 0.000233603
  hsa-miR-3619-5p    8.12123642    Down                 0.044123068
  hsa-miR-3657       2.25696259    Down                 0.029294154
  hsa-miR-548u       2.16192045    Down                 0.035163924
  hsa-miR-5699-5p    2.59881075    Down                 0.010750283
  hsa-miR-874-5p     3.76411255    Down                 0.007516669
  hsa-miR-4684-3p    2.80937387    Down                 0.03699219

###### 

The list of differentially expressed novel miRNAs between stable Smad4 overexpression cells and controls (*P*\<0.05, fold change \>2)

  miRNA            Fold change   Type of regulation   *P*-value
  ---------------- ------------- -------------------- -------------
                                                      
  novel-m0012-5p   11.537432     Down                 0.018215425
  novel-m0080-5p   29.89626      Down                 1.43E−05
  novel-m0084-5p   3.0550489     Down                 0.022574517
  novel-m0099-5p   63.828429     Down                 0.00013912
  novel-m0100-5p   63.828429     Down                 0.00013912
  novel-m0101-5p   63.828429     Down                 0.00013912
  novel-m0102-5p   63.828429     Down                 0.00013912
  novel-m0103-5p   63.828429     Down                 0.00013912
  novel-m0179-5p   2.8894051     Down                 0.027729009
  novel-m0333-3p   4.85719837    Down                 0.011391107
  novel-m0336-3p   4.85719837    Down                 0.011391107
  novel-m0246-3p   2.13677497    Down                 0.020091995
  novel-m0190-5p   2.88940513    Down                 0.027729009
  novel-m0188-5p   8.014228      Up                   0.036847661
  novel-m0030-5p   16.71333      Up                   0.000194285
  novel-m0227-3p   23.84         Up                   0.001772445
  novel-m0228-3p   23.84         Up                   0.001772445
  novel-m0251-5p   10.19173      Up                   0.025869475

###### 

The most significantly enriched GO terms for cellular component for the predicted targets of the differentially expressed miRNAs following Smad4 reexpression

  GO term                                    Cluster frequency (out of 31,172 genes)   Genome frequency of use (out of 50,073 genes)   *P*-value   Corrected *P*-value
  ------------------------------------------ ----------------------------------------- ----------------------------------------------- ----------- ---------------------
  intracellular part                         20,076 (64.4%)                            29,514 (58.9%)                                  1.17e−222   7.51e−221
  organelle                                  19,075 (61.2%)                            27,978 (55.9%)                                  6.33e−208   4.05e−206
  cytoplasm                                  14,727 (47.2%)                            21,188 (42.3%)                                  6.13e−183   3.92e−181
  intracellular organelle                    16,265 (52.2%)                            23,970 (47.9%)                                  2.35e−136   1.50e−134
  cytoplasmic part                           9,278 (29.8%)                             13,032 (26.0%)                                  5.87e−136   3.76e−134
  membrane-bounded organelle                 14,858 (47.7%)                            21,792 (43.5%)                                  1.26e−128   8.07e−127
  intracellular membrane-bounded organelle   14,858 (47.7%)                            21,792 (43.5%)                                  1.26e−128   8.07e−127
  intracellular                              20,779 (66.7%)                            31,419, 62.7%)                                  4.35e−119   2.78e−117
  cell part                                  23,565 (75.6%)                            36,179 (72.3%)                                  3.80e−101   2.43e−99
  cell                                       23,566((75.6%)                            36,183 (72.3%)                                  6.99e−101   4.47e−99
  cytosol                                    4,639 (14.9%)                             6,275 (12.5%)                                   6.12e−97    3.91e−95
  endomembrane system                        3,602 (11.6%)                             4,941 (9.9%)                                    3.82e−62    2.44e−60
  nucleus                                    11,000 (35.3%)                            16,350 (32.7%)                                  1.58e−59    1.01e−57
  cytoskeleton                               2,394 (7.7%)                              3,296 (6.6%)                                    8.56e−39    5.47e−37
  organelle part                             3,724 (11.9%)                             5,298 (10.6%)                                   1.36e−38    8.75e−37
  intracellular organelle part               3,724 (11.9%)                             5,298 (10.6%)                                   1.36e−38    8.75e−37

**Note:** Terms from the Ontology with *P*-value as good or better than 1.

**Abbreviation:** GO, Gene Ontology.

###### 

The most significantly enriched GO terms for molecular function for the predicted targets of the differentially expressed miRNAs following Smad4 reexpression

  GO term                                              Cluster frequency (out of 33,646 genes)   Genome frequency of use (out of 58,624 genes)   *P*-value   Corrected *P*-value
  ---------------------------------------------------- ----------------------------------------- ----------------------------------------------- ----------- ---------------------
  binding                                              18,591 (55.3%)                            29,447 (50.2%)                                  4.79e−176   3.02e−174
  protein binding                                      4,776 (14.2%)                             6,698 (11.4%)                                   2.12e−137   1.34e−135
  enzyme binding                                       2,345 (7.0%)                              3,122 (5.3%)                                    9.80e−100   6.17e−98
  nucleic acid binding                                 6,696 (19.9%)                             10,240 (17.5%)                                  5.83e−74    3.67e−72
  organic cyclic compound binding                      6,696 (19.9%)                             10,240 (17.5%)                                  5.83e−74    3.67e−72
  heterocyclic compound binding                        6,696 (19.9%)                             10,240 (17.5%)                                  5.83e−74    3.67e−72
  ion binding                                          12,255 (36.4%)                            19,725 (33.6%)                                  7.43e−62    4.68e−60
  DNA binding                                          4,403 (13.1%)                             6,729 (11.5%)                                   1.19e−46    7.55e−45
  protein binding transcription factor activity        1,023 (3.0%)                              1,373 (2.3%)                                    8.46e−41    5.33e−39
  transcription factor binding                         817 (2.4%)                                1,104 (1.9%)                                    3.82e−31    2.40e−29
  lipid binding                                        1,096 (3.3%)                              1,533 (2.6%)                                    4.59e−31    2.89e−29
  RNA binding                                          2,705 (8.0%)                              4,107 (7.0%)                                    7.84e−31    4.94e−29
  cytoskeletal protein binding                         1,611 (4.8%)                              2,365 (4.0%)                                    5.58e−28    3.51e−26
  enzyme regulator activity                            1,688 (5.0%)                              2,518 (4.3%)                                    2.50e−24    1.58e−22
  molecular function regulator                         1,688 (5.0%)                              2,518 (4.3%)                                    2.50e−24    1.58e−22
  nucleic acid binding transcription factor activity   2,103 (6.3%)                              3,197 (5.5%)                                    1.29e−23    8.15e−22
  transferase activity                                 3,641 (10.8%)                             5,885 (10.0%)                                   1.05e−13    6.67e−12
  histone binding                                      256 (0.8%)                                344 (0.6%)                                      3.29e−11    2.07e−09
  phosphatase activity                                 578 (1.7%)                                853 (1.5%)                                      2.49e−10    1.56e−08

**Note:** Terms from the function ontology with *P*-value as good or better than 1.

**Abbreviation:** GO, Gene Ontology.

###### 

The most significantly enriched GO terms for molecular biological process for the predicted targets of the differentially expressed miRNAs following Smad4 reexpression

  GO term                                         Cluster frequency (out of 30,854 genes)   Genome frequency of use (out of 51,743 genes)   *P*-value   Corrected *P*-value
  ----------------------------------------------- ----------------------------------------- ----------------------------------------------- ----------- ---------------------
  cellular process                                21,945 (71.1%)                            34,615 (66.9%)                                  2.03e−135   3.46e−133
  single-organism process                         16,897 (54.8%)                            26,171 (50.6%)                                  6.57e−119   1.11e−116
  developmental process                           4,416 (14.3%)                             6,062 (11.7%)                                   2.07e−115   3.52e−113
  single-organism cellular process                13,739 (44.5%)                            21,184 (40.9%)                                  2.93e−91    4.98e−89
  metabolic process                               15,628 (50.7%)                            24,384 (47.1%)                                  2.19e−85    3.72e−83
  biosynthetic process                            7,285 (23.6%)                             10,771 (20.8%)                                  1.50e−82    2.56e−80
  cellular metabolic process                      13,537 (43.9%)                            20,960 (40.5%)                                  7.92e−81    1.34e−78
  anatomical structure development                3,194 (10.4%)                             4,389 (8.5%)                                    1.82e−80    3.10e−78
  cellular component organization                 5,065 (16.4%)                             7,347 (14.2%)                                   4.72e−71    8.02e−69
  cellular component organization or biogenesis   5,107 (16.6%)                             7,419 (14.3%)                                   2.80e−70    4.76e−68
  cellular nitrogen compound metabolic process    8,866 (28.7%)                             13,540 (26.2%)                                  1.38e−59    2.35e−57
  nitrogen compound metabolic process             9,067 (29.4%)                             13,871 (26.8%)                                  3.37e−59    5.74e−57
  cell differentiation                            1,839 (6.0%)                              2,476 (4.8%)                                    2.66e−55    4.53e−53
  single-organism developmental process           2,283 (7.4%)                              3,161 (6.1%)                                    1.61e−52    2.75e−50
  Localization                                    7,104 (23.0%)                             10,785)20.8%)                                   8.54e−51    1.45e−48
  organelle organization                          1,865 (6.0%)                              2,574 (5.0%)                                    3.28e−44    5.58e−42
  cell--cell signaling                            1,117 (3.6%)                              1,475 (2.9%)                                    6.47e−40    1.10e−37
  cellular developmental process                  1,993 (6.5%)                              2,803 (5.4%)                                    1.02e−38    1.73e−36
  cell communication                              8,167 (26.5%)                             12,684 (24.5%)                                  7.68e−37    1.30e−34
  signaling                                       8,167 (26.5%)                             12,684 (24.5%)                                  7.68e−37    1.30e−34
  single organism signaling                       8,167 (26.5%)                             12,684 (24.5%)                                  7.68e−37    1.30e−34
  biological regulation                           8,400 (27.2%)                             13,094 (25.3%)                                  8.48e−35    1.44e−32

**Note:** Terms from the process ontology with *P*-value as good or better than 1.

**Abbreviation:** GO, Gene Ontology.

###### 

KEGG pathway analysis for the predicted targets of the differentially expressed miRNAs

  Pathway                                     Target genes with pathway annotation (15,068)   All genes of the species with pathway annotation (31,075)   *P*-value      Q-value        Pathway ID
  ------------------------------------------- ----------------------------------------------- ----------------------------------------------------------- -------------- -------------- ------------
  Vascular smooth muscle contraction          339 (2.25%)                                     551 (1.77%)                                                 3.817347e−10   6.353478e−08   ko04270
  Pathways in cancer                          1,004 (6.66%)                                   1,810 (5.82%)                                               5.294565e−10   6.353478e−08   ko05200
  Glutamatergic synapse                       336 (2.23%)                                     559 (1.8%)                                                  1.744324e−08   1.122107e−06   ko04724
  Folate biosynthesis                         44 (0.29%)                                      51 (0.16%)                                                  1.870179e−08   1.122107e−06   ko00790
  Cytokine--cytokine receptor interaction     524 (3.48%)                                     913 (2.94%)                                                 2.741697e−08   1.316015e−06   ko04060
  Calcium signaling pathway                   477 (3.17%)                                     826 (2.66%)                                                 4.015428e−08   1.606171e−06   ko04020
  Neuroactive ligand--receptor interaction    544 (3.61%)                                     961 (3.09%)                                                 1.834706e−07   6.290421e−06   ko04080
  Chemokine signaling pathway                 465 (3.09%)                                     813 (2.62%)                                                 2.844341e−07   8.533023e−06   ko04062
  Aldosterone-regulated sodium reabsorption   121 (0.8%)                                      181 (0.58%)                                                 4.371058e−07   1.165615e−05   ko04960
  Salivary secretion                          233 (1.55%)                                     383 (1.23%)                                                 7.001501e−07   1.680360e−05   ko04970
  Axon guidance                               385 (2.56%)                                     667 (2.15%)                                                 8.425047e−07   1.838192e−05   ko04360
  Fc gamma R-mediated phagocytosis            270 (1.79%)                                     455 (1.46%)                                                 1.864193e−06   3.728386e−05   ko04666
  GnRH signaling pathway                      274 (1.82%)                                     467 (1.5%)                                                  5.521091e−06   1.019278e−04   ko04912
  Melanogenesis                               260 (1.73%)                                     442 (1.42%)                                                 7.238362e−06   1.240862e−04   ko04916
  Progesterone-mediated oocyte maturation     290 (1.92%)                                     500 (1.61%)                                                 1.073179e−05   1.717086e−04   ko04914
  Prostate cancer                             338 (2.24%)                                     592 (1.91%)                                                 1.387196e−05   2.080794e−04   ko05215
  Regulation of actin cytoskeleton            584 (3.88%)                                     1,066 (3.43%)                                               1.634052e−05   2.306897e−04   ko04810
  Phosphatidylinositol signaling system       236 (1.57%)                                     402 (1.29%)                                                 2.244263e−05   2.992351e−04   ko04070
  ErbB signaling pathway                      294 (1.95%)                                     513 (1.65%)                                                 3.313052e−05   4.184908e−04   ko04012
  Oocyte meiosis                              328 (2.18%)                                     578 (1.86%)                                                 3.589737e−05   4.204091e−04   ko04114

**Note:** The significantly enriched pathways annotation for the predicted targets of the differentially expressed miRNAs following Smad4 reexpression.

**Abbreviation:** GnRH, gonadotropin-releasing hormone; KEGG, Kyoto Encyclopedia of Genes and Genomes.
